| All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy |
Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-15 17:00:44 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year' |
Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter the idiopathic hypersomnia market after a favorable court ruling. Analysts remain bullish, reiterating Buy ratings and projecting significant revenue and profit growth through FY2026 as LUMRYZ adoption accelerates. |
seekingalpha.com |
2025-05-15 15:43:39 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer |
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain. |
globenewswire.com |
2025-05-13 20:15:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference |
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m. |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy? |
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-05-12 17:20:41 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade |
The mean of analysts' price targets for Avadel (AVDL) points to a 100.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-12 15:00:57 |
Czytaj oryginał (ang.) |
| Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 51,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants. |
globenewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript |
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Mark Goodman - Leerink David Huang - Deutsche Bank Myriam Belghiti - LSC Ami Fadia - Needham Chase Knickerbocker - Craig Hallum Operator Greetings, and welcome to Avadel Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all participants are in a listen only mode. |
seekingalpha.com |
2025-05-07 16:45:09 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance |
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction |
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) has ruled in favor of Avadel, overturning important parts of the injunction imposed by the U.S. District Court for the District of Delaware (the “Delaware Court”) regarding LUMRYZ™ as a potential treatment of indications beyond narcolepsy. The Federal Circuit vacated the portion of the injunction that prohibited Avadel from applying for FDA approval of LUMRYZ for any indication beyond narcolepsy, calling the district court's analysis “simply too speculative and tenuous. |
globenewswire.com |
2025-05-06 16:30:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7 |
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience |
-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment, most often due to lack of efficacy; inability to wake up was most common reason for missing second nightly dose -- DUBLIN, April 17, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, and nference , a health tech company dedicated to making biomedical data computable, today announced the publication of real-world data on comorbidities and treatment patterns of people with narcolepsy treated versus not treated with immediate-release sodium oxybate. |
globenewswire.com |
2025-04-17 12:00:00 |
Czytaj oryginał (ang.) |
| Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 48,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants. |
globenewswire.com |
2025-04-10 20:05:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference |
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference. |
globenewswire.com |
2025-04-08 17:30:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference |
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET. |
globenewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians |
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled “A New Dawn in the Management of Narcolepsy”. |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Present at Upcoming Investor Conferences |
DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET. UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. |
globenewswire.com |
2025-03-05 10:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript |
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Austin Murtagh - Precision AQ Gregory Divis - Chief Executive Officer Thomas McHugh - Chief Financial Officer Conference Call Participants François Brisebois - Oppenheimer Poorna Kannan - Needham & Company Oren Livnat - H.C. Wainwright & Co. David Amsellem - Piper Sandler & Co. Madhumita Yennawar - Leerink Partners Myriam Belghiti - LifeSci Capital David Hoang - Deutsche Bank AG Brandon Folkes - Rodman & Renshaw Research Operator Greetings, and welcome to Avadel Pharmaceuticals' Fourth Quarter and Business Update Conference Call. |
seekingalpha.com |
2025-03-04 01:53:10 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results |
-- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 -- Reiterates 2025 guidance, with the number of patients on LUMRYZ expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million -- Executing multiple initiatives to accelerate patient demand for LUMRYZ -- Patient enrollment is on track in the Phase 3 REVITALYZ™ study to evaluate efficacy and safety of LUMRYZ in Idiopathic Hypersomnia (IH) -- Avadel management to host a conference call today at 8:30 a.m. ET DUBLIN, March 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3 |
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales |
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
DUBLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 173,000 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants. |
globenewswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals: Moving To A Speculative Buy |
Avadel Pharmaceuticals' primary asset, LUMRYZ, treats narcolepsy and is in Phase 3 trials for Idiopathic Hypersomnia, with significant revenue growth potential. Recent news includes the resignation of the Chief Commercial Officer, strong Q4 revenue growth, and a push from ASL Strategic Value Fund for strategic alternatives. Analysts are universally positive, with multiple Buy ratings and price targets ranging from $12 to $22, despite some downward revisions. |
seekingalpha.com |
2025-02-11 20:08:43 |
Czytaj oryginał (ang.) |
| ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors |
CHESTERFIELD, Mo.--(BUSINESS WIRE)--The following is a letter that ASL Strategic Value Fund sent to the Board of Directors of Avadel Pharmaceuticals (NASDAQ:AVDL): February 10, 2025 Mr. Geoff Glass Chairman, Board of Directors Avadel Pharmaceuticals Plc 16640 Chesterfield Grove Road, Suite 200 Chesterfield, Mo 63005 Dear Geoff: As you are aware, the ASL Strategic Value Fund has been a long-term investor in Avadel Pharmaceuticals. Our ownership predates most of the directors on the current Board. |
businesswire.com |
2025-02-10 11:00:00 |
Czytaj oryginał (ang.) |
| There May Still Be Time to Get in on These 3 Trending Biotechs |
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms. |
marketbeat.com |
2025-01-20 10:15:25 |
Czytaj oryginał (ang.) |
| 3 Oversold Biotech Names |
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels. |
seekingalpha.com |
2025-01-13 14:56:03 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook |
Avadel Pharmaceuticals' 2025 net sales guidance for Lumryz was significantly below expectations due to increasing patient attrition. The company is increasing efforts to address some of these challenges and to increase uptake among patients switching from other oxybates. Last year's legal updates have significantly reduced the risk of ruin, with Lumryz staying on the market for narcolepsy, but there was also the loss on the idiopathic hypersomnia side. |
seekingalpha.com |
2025-01-12 05:26:06 |
Czytaj oryginał (ang.) |
| Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch |
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter -- |
globenewswire.com |
2025-01-08 18:15:00 |
Czytaj oryginał (ang.) |
| Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to twelve (12) new employees to purchase an aggregate of 131,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants. |
globenewswire.com |
2025-01-06 18:05:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 |
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-01-03 10:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference |
DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. |
globenewswire.com |
2024-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript |
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - CEO Richard Kim - CCO Jennifer Gudeman - SVP, Medical & Clinical Affairs Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Oren Livnat - H.C. Wainwright Ami Fadia - Needham David Amsellem - Piper Sandler Operator Good day everyone and welcome to today's Avadel Pharmaceuticals 3Q 2024 Earnings Call. |
seekingalpha.com |
2024-11-12 17:19:28 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation |
DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S. District Court for the District of Columbia (“Court”) ruled in favor of the Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) under the Administrative Procedure Act regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in adults with narcolepsy. With this ruling, the approval of LUMRYZ is upheld based on the FDA's determination that LUMRYZ is clinically superior to Jazz's twice-nightly oxybate products. |
globenewswire.com |
2024-10-31 09:00:00 |
Czytaj oryginał (ang.) |
| Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz |
The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy. |
zacks.com |
2024-10-18 14:41:23 |
Czytaj oryginał (ang.) |
| US FDA expands approval for Avadel's sleep disorder drug |
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and older, broadening its use and heating up competition for widely used treatments from Jazz Pharma. |
reuters.com |
2024-10-17 14:03:36 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy |
-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— |
globenewswire.com |
2024-10-17 13:41:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII) |
– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens – |
globenewswire.com |
2024-09-03 12:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Present at Upcoming Investor Conferences |
DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-08-28 12:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript |
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - Chief Executive Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Senior Vice President, Medical & Clinical Affairs Tom McHugh - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Ami Fadia - Needham & Company David Amsellem - Piper Sandler Marc Goodman - Leerink Fatima Amanat - UBS Oren Livnat - H.C. Wainwright Myriam Belghiti - LifeSci Capital Matt Kaplan - Ladenburg Thalmann Brandon Folkes - Rodman & Renshaw Operator Greetings, and welcome to Avadel Pharmaceuticals' Second Quarter 2024 Earnings Call. |
seekingalpha.com |
2024-08-09 16:27:08 |
Czytaj oryginał (ang.) |
| Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-08-05 15:01:23 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Join Russell 3000® Index |
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. |
globenewswire.com |
2024-06-27 20:05:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Present at Upcoming Investor Conferences |
DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-05-30 12:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024 |
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – |
globenewswire.com |
2024-05-22 12:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors |
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. |
globenewswire.com |
2024-05-21 11:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results |
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy -- |
globenewswire.com |
2024-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 |
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. |
globenewswire.com |
2024-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-04-29 14:56:07 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution |
Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges. |
seekingalpha.com |
2024-04-02 07:40:17 |
Czytaj oryginał (ang.) |
| Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference |
DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET. |
globenewswire.com |
2024-04-01 12:00:00 |
Czytaj oryginał (ang.) |